Bayer wins U.S. priority review of drug against metastatic prostate cancer

FRANKFURT, May 3 (Reuters) – Bayer’s (BAYGn.DE) Nubeqa drug won priority review status from the U.S. Food and Drug Administration, as the German drugmaker seeks to widen the use of the prostate cancer drug from an early disease stage to metastatic cases.

Logo of Bayer AG is pictured at the annual results news conference of the German drugmaker in Leverkusen, Germany February 27, 2019. REUTERS/Wolfgang Rattay

The priority status was granted as the U.S. regulatory body accepted Bayer’s supplemental New Drug Application (sNDA) for the use of Nubeqa, jointly developed with Finnish drugmaker Orion (ORNBV.HE), against metastatic hormone-sensitive prostate cancer, Bayer said in a statement on Tuesday.

Reporting by Ludwig Burger, Editing by Miranda Murray

Our Standards: The Thomson Reuters Trust Principles.


Reuters source: